Your browser doesn't support javascript.
loading
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig, Noemí; Contreras, María-Teresa; Agulló, Cristina; Martínez-López, Joaquín; Oriol, Albert; Blanchard, María-Jesús; Ríos, Rafael; Martín, Jesús; Iñigo, María-Belén; Sureda, Anna; Hernández, Miguel-Teodoro; de la Rubia, Javier; González-Calle, Verónica; Krsnik, Isabel; Cabañas, Valentín; Palomera, Luis; Moraleda, José-María; Bargay, Joan; Cedena, María-Teresa; Paiva, Bruno; Rosiñol, Laura; Bladé, Joan; San Miguel, Jesús; Lahuerta, Juan-José; Mateos, María-Victoria.
Afiliación
  • Puig N; Hematology Department, IBSAL, Instituto de Biología Molecular y Celular del Cáncer-Consejo Superior de Investigaciones Científicas (IBMCC-CSIC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).
  • Contreras MT; Clinical Biochemistry Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Agulló C; Clinical Biochemistry Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Martínez-López J; Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, CIBERONC CB16/12/00369, Madrid, Spain.
  • Oriol A; Institut Català d'Oncologia, Institut Josep Carreras Hospital Germans i Trials, Barcelona, Spain.
  • Blanchard MJ; Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
  • Ríos R; Hematology Department, Hospital Universitario Virgen de las Nieves, Ibs. GRANADA, CIBERESP, Granada, Spain.
  • Martín J; Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Iñigo MB; Hospital Clínico San Carlos, Madrid, Spain.
  • Sureda A; Institut Catalá d'Oncologia-l'Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Hernández MT; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
  • de la Rubia J; Department of Hematology, University Hospital Le Fe and School of Medicine and Dentistry, Catholic University of Valencia, CIBERONC CB16/12/00284, Valencia, Spain.
  • González-Calle V; Hematology Department, IBSAL, Instituto de Biología Molecular y Celular del Cáncer-Consejo Superior de Investigaciones Científicas (IBMCC-CSIC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).
  • Krsnik I; Hospital Puerta de Hierro, Madrid, Spain.
  • Cabañas V; Hospital Universitario Virgen de la Arrixaca, IMIB, Murcia, Spain.
  • Palomera L; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Moraleda JM; Hospital Universitario Virgen de la Arrixaca, IMIB, Murcia, Spain.
  • Bargay J; Hospital Son Llatzer, Palma de Mallorca, Spain.
  • Cedena MT; Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, CIBERONC CB16/12/00369, Madrid, Spain.
  • Paiva B; Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC CB16/12/00369, Pamplona, Spain.
  • Rosiñol L; Hospital Clinic, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; and.
  • Bladé J; Hospital Clinic, Institut d'Investigacions Biomédiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain; and.
  • San Miguel J; Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC CB16/12/00369, Pamplona, Spain.
  • Lahuerta JJ; Instituto de Investigación del Hospital Universitario 12 de Octubre, CIBERONC, Madrid, Spain.
  • Mateos MV; Hematology Department, IBSAL, Instituto de Biología Molecular y Celular del Cáncer-Consejo Superior de Investigaciones Científicas (IBMCC-CSIC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).
Blood Adv ; 6(11): 3234-3239, 2022 06 14.
Article en En | MEDLINE | ID: mdl-35157768
Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE- cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE- patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos